Sorrento’s COVID-19 Antidote Could be a Game Changer, Says Analyst
Oxygen for all, during COVID-19 (coronavirus) and beyond
Peer-reviewed data shows remdesivir for COVID-19 improves time to recovery
Sanofi sheds Regeneron stake, but insists collaboration is unaffected
Fate Therapeutics (FATE) Cleared By FDA of IND Application for FT538
7 "Perfect 10" Stocks to Buy Now
Gilead’s Remdesivir Most ‘Beneficial’ In Covid-19 Patients Who Need Extra Oxygen, Study Shows
Researchers define exactly what they saw in the first positive remdesivir study for Covid-19. But what's that worth to Gilead?
Some patients with bladder cancer ‘can’t wait’ for treatment during the COVID-19 pandemic
3 "Strong Buy" Biotech Stocks Under $5 With Massive Upside Potential
Airway Therapeutics, Celonic Group partner to produce AT-100 as candidate for coronavirus
Gilead, Galapagos claim PhIIb/III win for filgotinib in ulcerative colitis — which pales in comparison to rivals
Gilead Still Holds the Winning Hand, Says 5-Star Analyst
Statistical approach to COVID-19 clinical trials aims to accelerate drug approval process
X-ray experiments zero in on COVID-19 antibodies
Sorrento (SRNE) Stock Is up 140% in Two Days. How Much Higher Can It Go?
New study sheds light on IBD patients with COVID
Bob Langer-founded cell therapy player loads up $65M to fund Roche-partnered cancer work while expanding into vaccines for infectious diseases
UHN-U of T-led study shows antiviral drug can speed up recovery of COVID-19 patient
Cherry Thomas joins Caribou as SVP of clinical development; Artax locks in Joseph Lobacki as CEO
Inovio (INO) Offers More Than Just a COVID-19 Vaccine, Says Top Analyst
3 Biotech Stocks Under $4 That Could Surge Over 50%
3 "Strong Buy" Penny Stocks With Triple-Digit Upside
Fate Therapeutics (FATE) Earnings Report Highlights for Q1 2020
3 Biotech Stocks Under $4 With Massive Upside Ahead
Skilled partners in the conduct of HIV prevention trials join COVID-19 response
Can Digital Therapeutics Save the Future of Healthcare?
3 Biotech Stocks Under $4 With at Least 50% Upside Potential
Morgan Stanley: 2 Stocks That Could Surge Over 25%
Epic CEO Judy Faulkner on developing new therapies for COVID-19